Articles

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

University of Milano-Bicocca, Monza, Italy
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Princess Margaret Cancer Centre, Toronto, ON, Canada
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Seoul St. Mary’s Hospital, South Korea
Department of Internal Medicine II, Hubertus Wald Tumor Center-University Cancer Center Hamburg, Germany
Pfizer Inc., Collegeville, PA, USA
Pfizer Global Research and Development, Paris, France
Pfizer Inc., Cambridge, MA, USA
Pfizer Inc., Groton, CT, USA
Pfizer Inc., Cambridge, MA, USA
Pfizer Inc., Collegeville, PA, USA
Department of Internal Medicine II, Hubertus Wald Tumor Center-University Cancer Center Hamburg, Germany;Universitätsklinikum RWTH Aachen, Germany
Winship Cancer Institute of Emory University, Atlanta, GA, USA
Vol. 103 No. 8 (2018): August, 2018 https://doi.org/10.3324/haematol.2017.171249